Oncoinvent ASA
0RU5StockLSE
0.43 ▼ 1.14%
03 juin 2026
0
Oncoinvent ASA
0.43 ▼ 1.14%
03 juin 2026
0RU5StockLSE

01 / À propos

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.

Arberion
Loading market data